Nanolive will be present at the ASCB|EMBO meeting this year in Washington D.C., from the 3rd to the 7th of December, where we’ll be showcasing our vast range of label-free high content phenotypic solutions, that combine screening, imaging, and analysis to radically advance the study of living cells and provide novel biological insights.
If you are attending the meeting, don’t miss the opportunity to visit our team at booth #2225, to book your demo or to get more information on the latest tools to accelerate your drug discovery and to help you getting higher significance, earlier and faster!
Tech Talk
Join us for a tech talk “Nanolive: A Label-free High Content Phenotypic Solution for De-risking Drug Discovery and Development for Immuno-oncology, Cell Metabolism and Cytotoxicity Studies” on December 5th from 3.15 to 4.00pm, in Theater 1, presented by our US General Manager Jonathan Day and Scientific Communication Specialist Hope Amos.
Read our latest news
Revolutionizing lipid droplet analysis: insights from Nanolive’s Smart Lipid Droplet Assay Application Note
Introducing the Smart Lipid Droplet Assay: A breakthrough in label-free lipid droplet analysis Discover the power of Nanolive's Smart Lipid Droplet Assay (SLDA), the first smart digital assay to provide a push-button solution for analyzing lipid droplet dynamics,...
Food additives and gut health: new research from the University of Sydney
The team of Professor Wojciech Chrzanowski in the Sydney Pharmacy School at the University of Sydney have published their findings on the toxic effect of titanium nanoparticles found in food. The paper “Impact of nano-titanium dioxide extracted from food products on...
2023 scientific publications roundup
2023 has been a record year for clients using the Nanolive system in their scientific publications. The number of peer-reviewed publications has continued to increase, and there has been a real growth in groups publishing pre-prints to give a preview of their work....
